Analytical Data
-
Gene name
RT0041
- Application
-
Alternative Names
/
-
Species
Rickettsia typhi
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q68XW4
-
Expression Region
70-147aa
-
Molecular Weight
15.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RT0041 is a recombinant protein that has garnered attention in the field of biomedical research due to its potential applications in therapeutic development and disease modeling. The background of the study on RT0041 stems from the increasing interest in protein-based therapies, particularly in tackling complex diseases such as cancer and autoimmune disorders. This protein is derived from a specific gene that encodes for a protein involved in critical biological processes, including cell signaling and immune response modulation. As researchers seek to understand the underlying mechanisms of various diseases, the study of RT0041 provides insight into its structural and functional characteristics. Investigations have shown that RT0041 may play a role in enhancing cellular responses, making it a candidate for targeted therapies. Furthermore, the recombinant production of RT0041 allows for large-scale availability and standardized quality, which is crucial for preclinical and clinical applications. By elucidating the properties and mechanisms of action of RT0041, researchers aim to explore its potential as a therapeutic agent and its implications in advancing personalized medicine. Overall, the study of RT0041 not only contributes to our understanding of protein functionality but also opens avenues for innovative treatment strategies in various diseases.
